

Supplemental Table 4. Excluded reviews

Excluded review	Comment
Abu-Khalf 2013 <sup>1</sup>	Not a systematic review
Bellcross 2010 <sup>2</sup>	Not a systematic review
BCBS Tech 2010 <sup>3</sup>	We did not consider this to be a systematic review; did not describe comprehensive search strategy, specified inclusion criteria, or method for quality assessment of included studies.
BCBS Tech 2008 <sup>4</sup>	We did not consider this to be a systematic review; did not describe comprehensive search strategy, specified inclusion criteria, or method for quality assessment of included studies.
Carlson 2013 <sup>5</sup>	Systematic review evaluating key question 2 but did not assess methodological quality of included studies
Chung 2013 <sup>6</sup>	Systematic review that did not evaluate any of the three key questions
ESMO 2009 <sup>7</sup>	Guideline statement; not a systematic review
ESMO 2010 <sup>8</sup>	Guideline statement; not a systematic review
IMPAKT 2012 <sup>9</sup>	Guideline statement; not a systematic review
Ishibe 2011 <sup>10</sup>	Not a systematic review
Marchionni 2008 <sup>11</sup>	Original systematic review for EGAPP recommendation.
Markopoulos 2013 <sup>12</sup>	Not a systematic review
Mihaly 2013 <sup>13</sup>	Systematic review that did not evaluate any of the three key questions

1. Abu-Khalf M, Pusztai L. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. *Breast* 2013; 22(S2): S83-S87.
2. Bellcross C, Dotson WD. Tumor gene expression profiling in women with breast cancer. *PLOS Currents Evidence on Genomic Tests*. 2010 Sep 1. Edition 1. doi: 10.1371/currents.RRN1178.
3. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy. *Technology Evaluation Center Assessment Program*. 2008; 22 (13): 1-8.
4. Gene expression profiling in women with lymph-node-positive breast cancer to select adjuvant chemotherapy treatment. *Technology Evaluation Center Assessment Program*. 2010; 25(1):1-4.
5. Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2013; 141(1): 13-22.
6. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. *J Oncol Pharm Pract*. 2013; Mar 14. [Epub ahead of print]
7. Kataja V, Castiglione M. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Annals of Oncology*. 2009; 20(Supplement 4): iv10-iv14.
8. Aebi S, Davidon T, Gruber G, Castiglione M. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2010; 21 (Supplement 5): v9-v14.
9. Azim HA, Michiels S, Zagouri F, Delagoe S, Filipits M, Namer M, et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. *Annals of Oncology*. 2013; 00: 1-8.

10. Ishibe N, Schully S, Freedman A, Ramsey SD. Use of Oncotype DX in Women with Node-Positive Breast Cancer. *PLOS Currents Evidence on Genomic Tests*. 2011 Jul 21. Edition 1. doi: 10.1371/currents.RRN1249.
11. Marchionni L, Wilson RF, Marinopoulos SS, et al. Impact of gene expression profiling tests on breast cancer outcomes. *Evid Rep Technol Assess (Full Rep)*. 2007(160):1-105.
12. Markopoulos C. Overview of the use of Oncotype DX((R)) as an additional treatment decision tool in early breast cancer. *Expert Rev Anticancer Ther*. 2013; 13(2): 179-194.
13. Mihaly Z, Kormos M, Lanczky A, Dank M, Budczies J, Szas MA, Gyorffy B. A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. *Breast Cancer Res Treat*. 2013; 140(2): 219-32.